Stockscreener 앱 받기
4.79
2.35%
0.11
시간 외 거래:
4.50
-0.29
-6.05%
전일 마감가:
$4.68
열려 있는:
$4.61
하루 거래량:
68,124
Relative Volume:
0.46
시가총액:
$480.56M
수익:
$5.15M
순이익/손실:
$-65.35M
주가수익비율:
-3.5481
EPS:
-1.35
순현금흐름:
$-20.85M
1주 성능:
+3.68%
1개월 성능:
+22.82%
6개월 성능:
+260.15%
1년 성능:
+172.16%
1일 변동 폭
$4.55
$4.90
1주일 범위
$4.47
$5.45
52주 변동 폭
$1.10
$5.4796
Cellectis Adr Stock (CLLS) Company Profile
CLLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CLLS
Cellectis Adr
|
4.79 | 469.52M | 5.15M | -65.35M | -20.85M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cellectis Adr Stock (CLLS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-17 | 개시 | Bryan Garnier | Buy |
| 2022-05-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2021-11-30 | 개시 | JMP Securities | Mkt Outperform |
| 2021-11-08 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2021-04-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2020-08-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-12 | 개시 | Robert W. Baird | Outperform |
| 2020-03-06 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-10-30 | 재개 | Guggenheim | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-05-24 | 재개 | Citigroup | Neutral |
| 2019-03-14 | 개시 | William Blair | Outperform |
| 2018-12-19 | 개시 | Goldman | Neutral |
| 2018-07-16 | 개시 | Barclays | Overweight |
| 2018-03-16 | 개시 | Guggenheim | Neutral |
| 2017-09-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2017-09-05 | 재확인 | Wells Fargo | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2017-02-28 | 개시 | Wells Fargo | Outperform |
| 2016-04-05 | 개시 | Ladenburg Thalmann | Buy |
| 2016-03-02 | 개시 | Sun Trust Rbsn Humphrey | Buy |
| 2015-07-20 | 개시 | BofA/Merrill | Buy |
| 2015-04-20 | 개시 | Jefferies | Buy |
| 2015-04-20 | 개시 | Piper Jaffray | Overweight |
모두보기
Cellectis Adr 주식(CLLS)의 최신 뉴스
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL - GlobeNewswire Inc.
European ADRs Stay Put As Novo Nordisk Slides - Finimize
12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
Moligo and Cellectis show promise in non-viral gene editing method - Investing.com India
Moligo Technologies and Cellectis Demonstrate Potential of Enzymatic Single-Stranded DNA for Non-Viral Gene Editing in Nature Communications - Sahm
Why Cellectis Stock Is Trading Higher Today - Sahm
Citizens maintains Cellectis stock rating with $8 target ahead of ASH update - Investing.com
European ADRs Slip As Gains And Losses Balance Out - Finimize
European ADRs Dip As Biotech Stocks Tumble In US Trading - Finimize
Barclays Remains a Buy on Cellectis SA (CLLS) - The Globe and Mail
Barclays raises Cellectis stock price target to $8 on promising cancer therapy - Investing.com Philippines
Jefferies raises Cellectis stock price target to $6 after R&D day - Investing.com
Enerpac Tool Group Posts Upbeat Results, Joins Praxis Precision Medicines, J B Hunt, Salesforce And Other Big Stocks Moving Higher On Thursday - Benzinga
Operating cash flow per share of Cellectis S.A. Sponsored ADR – LSX:A14QZE - TradingView
Pre Market Movers: NBTX, IMTX, QNRX See Big Swings - RTTNews
A look into Cellectis ADR (CLLS)’s deeper side - Setenews
Cellectis’s SWOT analysis: gene therapy firm’s stock poised for growth? - Investing.com
European Pharma And Biotech Companies Led ADR Gains In The US - Finimize
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
European Stocks In The US Close The Week Mostly Steady - Finimize
European Equities Traded in the US as ADRs Fall in Friday Trading - 富途牛牛
Biotech And Tech Firms Drive Gains For European ADRs - Finimize
European ADRs Dip Slightly As Biotech Stocks Jump And Drop - Finimize
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates - ADVFN Brasil
European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest
Cellectis’s SWOT analysis: gene therapy firm’s stock faces pivotal moment - Investing.com
Earnings call transcript: Cellectis Q2 2025 earnings miss drives stock down 13% - Investing.com
Cellectis earnings missed by $0.02, revenue topped estimates - Investing.com India
Cellectis earnings missed by $0.02, revenue topped estimates By Investing.com - Investing.com South Africa
European Stocks Dip As US Holders Turn Cautious - Finimize
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
European ADRs Inch Higher As Drugmakers Shine - Finimize
Cellectis Adr (CLLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):